Subscribe
shutterstock_528642268-1
31 July 2019AmericasSarah Morgan

Alkermes settles with Amneal over opioid dependence treatment

Biopharmaceutical company  Alkermes has entered into a settlement and licence agreement with generic maker  Amneal Pharmaceuticals to resolve an inter partes review (IPR).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.

More on this story

Big Pharma
PTAB institutes IPR of Nalox-1 opioid overdose treatment
29 August 2019   The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Americas
Alkermes and Janssen enter arbitration over nanocrystal tech
21 April 2022   Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York